These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 7037980)

  • 41. Acetazolamide is an effective adjunct for urinary alkalization in patients with uric acid and cystine stone formation recalcitrant to potassium citrate.
    Sterrett SP; Penniston KL; Wolf JS; Nakada SY
    Urology; 2008 Aug; 72(2):278-81. PubMed ID: 18533229
    [TBL] [Abstract][Full Text] [Related]  

  • 42. [On the diuretic and saluretic activity of p-hydroxytriamterene and methoxytriamterene (author's transl)].
    Vollmer G; Mutschler E; Völger KD
    Arzneimittelforschung; 1981; 31(3):529-30. PubMed ID: 7194678
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Local factors compared with systemic factors in the formation of bladder uric acid stones.
    Li WM; Chou YH; Li CC; Liu CC; Huang SP; Wu WJ; Huang CH
    Urol Int; 2009; 82(1):48-52. PubMed ID: 19172097
    [TBL] [Abstract][Full Text] [Related]  

  • 44. [Analytical evaluation of urinary calculi mineral composition].
    Machoy P
    Ann Acad Med Stetin; 1995; 41():259-71. PubMed ID: 8615550
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Long-term incidence and risks for recurrent stones following contemporary management of upper tract calculi in patients with a urinary diversion.
    Cohen TD; Streem SB; Lammert G
    J Urol; 1996 Jan; 155(1):62-5. PubMed ID: 7490899
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Felodipine extended release versus conventional diuretic therapy for the treatment of systolic hypertension in elderly patients. The National Trial Group.
    McClennen W; Wilson T
    Clin Invest Med; 1998 Jun; 21(3):142-50. PubMed ID: 9627768
    [TBL] [Abstract][Full Text] [Related]  

  • 47. [On the bioavailability of hydrochlorothiazide and triamterene from commercial drugs (author's transl)].
    Knauf H; Möhrke W; Mutschler E; Völger KD
    Arzneimittelforschung; 1980; 30(6):1001-4. PubMed ID: 7191258
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Pattern of urinary tract stone diseases in Mekelle, Ethiopia.
    Alemu MH
    Ethiop Med J; 2008 Jul; 46(3):237-41. PubMed ID: 19271387
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Crystal retention in renal stone disease: a crucial role for the glycosaminoglycan hyaluronan?
    Verkoelen CF
    J Am Soc Nephrol; 2006 Jun; 17(6):1673-87. PubMed ID: 16707562
    [TBL] [Abstract][Full Text] [Related]  

  • 50. [The most important factor for active urinary stone formation in patients with urolithiasis].
    Simić-Ogrizović S; Dopsaj V; Jovicić S; Milenković D; Jovanović D; Nesić V
    Med Pregl; 2007; 60 Suppl 2():117-20. PubMed ID: 18928175
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Impact of stone location on success rates of endoscopic lithotripsy for nephrolithiasis.
    Perlmutter AE; Talug C; Tarry WF; Zaslau S; Mohseni H; Kandzari SJ
    Urology; 2008 Feb; 71(2):214-7. PubMed ID: 18308086
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Metabolic fate and solubility of triamterene--not an explanation for triamterene nephrolithiasis.
    Sörgel F; Ettinger B; Benet LZ
    J Pharm Sci; 1986 Feb; 75(2):129-32. PubMed ID: 3958920
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Triamterene stones and computerized axial tomography.
    Guevara A; Springmann KE; Drach GW; Hillman BJ
    Urology; 1986 Feb; 27(2):104-6. PubMed ID: 3946031
    [TBL] [Abstract][Full Text] [Related]  

  • 54. [Distribution volume and elimination of triamterene and its active metabolites in the rabbit (author's transl)].
    Knauf H; Mutschler E; Wais S; Wais U
    Arzneimittelforschung; 1978; 28(8):1414-6. PubMed ID: 582408
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Triamterene-induced nephrolithiasis.
    Grunberg RW; Silberg SJ
    JAMA; 1981 Jun; 245(24):2494-5. PubMed ID: 7230485
    [No Abstract]   [Full Text] [Related]  

  • 56. Triamterene stone: advantage of crystallographic analysis.
    Watson RA; Ettinger B; Deshon GE; Agee RE; Oldroyd NO
    Urology; 1981 Sep; 18(3):238-40. PubMed ID: 6269267
    [TBL] [Abstract][Full Text] [Related]  

  • 57. [Aminopenicillin crystalluria: identification by infrared spectrophotometry].
    Moesch C; Rince M; Raby C; Leroux-Robert C
    Ann Biol Clin (Paris); 1985; 43(3):227-31. PubMed ID: 4025964
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Triamterene-induced nephrolithiasis.
    Socolow EL
    Ann Intern Med; 1980 Mar; 92(3):437. PubMed ID: 7356247
    [No Abstract]   [Full Text] [Related]  

  • 59. Triamterene-induced nephrolithiasis.
    Ettinger B; Weil E; Mandel NS; Darling S
    Ann Intern Med; 1979 Nov; 91(5):745-6. PubMed ID: 496113
    [No Abstract]   [Full Text] [Related]  

  • 60. Triamterene bladder calculus.
    Hollander JB
    Urology; 1987 Aug; 30(2):154-5. PubMed ID: 3617299
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.